Concentrations of Co-Administered Meropenem and Vancomycin in Spinal Tissues Relevant for the Treatment of Pyogenic Spondylodiscitis—An Experimental Microdialysis Study
-
Published:2023-05-14
Issue:5
Volume:12
Page:907
-
ISSN:2079-6382
-
Container-title:Antibiotics
-
language:en
-
Short-container-title:Antibiotics
Author:
Slater Josefine123ORCID, Stilling Maiken123ORCID, Hanberg Pelle13, Vittrup Sofus123ORCID, Bruun Knudsen Martin123, Kousgaard Tøstesen Sara123ORCID, Olsen Kipp Josephine123, Bue Mats123ORCID
Affiliation:
1. Department of Orthopaedic Surgery, Aarhus University Hospital, 8200 Aarhus, Denmark 2. Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark 3. Aarhus Denmark Microdialysis Research (ADMIRE), Orthopaedic Research Laboratory, Aarhus University Hospital, 8200 Aarhus, Denmark
Abstract
Co-administration of meropenem and vancomycin has been suggested as a systemic empirical antibiotic treatment of pyogenic spondylodiscitis. The aim of this study was, in an experimental porcine model, to evaluate the percentage of an 8-h dosing interval of co-administered meropenem and vancomycin concentrations above the relevant minimal inhibitory concentrations (MICs) (%T>MIC) in spinal tissues using microdialysis. Eight female pigs (Danish Landrace breed, weight 78–82 kg) received a single-dose bolus infusion of 1000 mg of meropenem and 1000 mg vancomycin simultaneously before microdialysis sampling. Microdialysis catheters were applied in the third cervical (C3) vertebral cancellous bone, the C3–C4 intervertebral disc, paravertebral muscle, and adjacent subcutaneous tissue. Plasma samples were obtained for reference. The main finding was that for both drugs, the %T>MICs were highly reliant on the applied MIC target, but were heterogeneous across all targeted tissues, ranging from 25–90% for meropenem, and 10–100% for vancomycin. For both MIC targets, the highest %T>MIC was demonstrated in plasma, and the lowest %T>MIC was demonstrated in the vertebral cancellous bone for meropenem, and in the intervertebral disc for vancomycin. When indicated, our findings may suggest a more aggressive dosing approach of both meropenem and vancomycin to increase the spinal tissue concentrations to treat the full spectrum of potentially encountered bacteria in a spondylodiscitis treatment setting.
Funder
Orthopaedic Research Unit, Aarhus University Hospital
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference40 articles.
1. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults;Berbari;Clin. Infect. Dis.,2015 2. Vertebral osteomyelitis: Long-term outcome for 253 patients from 7 Cleveland-area hospitals;McHenry;Clin. Infect. Dis.,2002 3. Lang, S., Fromming, A., Walter, N., Freigang, V., Neumann, C., Loibl, M., Ehrenschwender, M., Alt, V., and Rupp, M. (2021). Is There a Difference in Clinical Features, Microbiological Epidemiology and Effective Empiric Antimicrobial Therapy Comparing Healthcare-Associated and Community-Acquired Vertebral Osteomyelitis?. Antibiotics, 10. 4. Quality of life and mortality after surgical treatment for vertebral osteomyelitis (VO): A prospective study;Yagdiran;Eur. Spine J.,2021 5. Infections of the Spine;Babic;Infect. Dis. Clin. N. Am.,2017
|
|